ANIXA BIOSCIENCES INC (NASDAQ: ANIX)

ANIXA BIOSCIENCES INC

NASDAQ: ANIX (Anixa Biosciences, Inc.)

Kemas kini terakhir: 25 Dec, 2025, 7:27PM

3.42

0.12 (3.64%)

Tambah ke senarai pantauan

Penutupan Terdahulu	3.30
Buka	3.31
Jumlah Dagangan	74,693
Purata Dagangan (3B)	320,617
Modal Pasaran	112,575,856

Harga / Buku (P/B)

6.19

Julat 52 Minggu	2.07 (-39%) — 5.46 (59%)
Tarikh Pendapatan	9 Jan 2026

Arah Aliran Pasaran

		Jangka Pendek	Jangka Sederhana
Industri	Biotechnology (US)	Menaik	Bercampur
	Biotechnology (Global)	Menaik	Bercampur
Stok	Anixa Biosciences, Inc.	Menaik	Menaik

AISkor Stockmoo

1.1

Konsensus Penganalisis	3.5
Aktiviti Orang Dalam	NA
Volatiliti Harga	-1.0
Purata Bergerak Teknikal	2.5
Osilator Teknikal	-0.5
Purata	1.13

Saham Serupa

Stok	Modal Pasaran	DY	P/E (TTM)	P/B
ANIX	113 M	-	-	6.19
IONS	13 B	-	-	20.95
RYTM	8 B	-	-	47.09
IMVT	5 B	-	-	10.04
SRRK	4 B	-	-	19.02
TERN	4 B	-	-	15.36

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Sektor	Healthcare
Industri	Biotechnology
Gaya Pelaburan	Small Core
% Dimiliki oleh Orang Dalam	5.32%
% Dimiliki oleh Institusi	17.60%

Pemilikan

Nama	Tarikh	Syer Dipegang
Laird Norton Wetherby Trust Company, Llc	30 Sep 2025	597,235

Julat 52 Minggu	2.07 (-39%) — 5.46 (59%)
Median	10.00 (192.40%)
Jumlah	1 Beli

Syarikat	Tarikh	Harga Sasaran	Panggilan	Harga @ Panggilan
D. Boral Capital	12 Dec 2025	10.00 (192.40%)	Beli	3.58

Tiada data dalam julat masa ini.

Tarikh	Jenis	Butiran
15 Dec 2025	Pengumuman	Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
11 Dec 2025	Pengumuman	Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
10 Dec 2025	Pengumuman	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
17 Nov 2025	Pengumuman	Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
12 Nov 2025	Pengumuman	Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s
10 Nov 2025	Pengumuman	Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025
05 Nov 2025	Pengumuman	Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic
23 Oct 2025	Pengumuman	Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
20 Oct 2025	Pengumuman	Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

Log masuk untuk menambahkan ke senarai pantauan

AI Templat

Peringatan harga anda

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Log masuk untuk menambahkan ke senarai pantauan

Keuntungan Nyata	-
Keuntungan Tidak Nyata	-
Dividen Diterima 2026	-
Jumlah Untung	-
Pulangan Purata	-
Kuantiti (Beli)	-
Purata Harga (Beli)	-
Kuantiti (Jual)	-
Purata Harga (Jual)	-

Log masuk untuk menambahkan ke senarai pantauan

Tiada saham yang memenuhi kriteria anda

Jumlah Hutang/Ekuiti (D/E MRQ)	1.48%
Nisbah Semasa (MRQ)	8.89
Aliran Tunai Operasi (OCF TTM)	-7.98 M
Aliran Tunai Bebas Leveraj (LFCF TTM)	-3.59 M

Pulangan Atas Aset (ROA TTM)	-39.75%
Pulangan Atas Ekuiti (ROE TTM)	-65.38%

Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)